Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
The American Board of Regenerative Medicine has endorsed AEON Clinic, the first regenerative wellness facility in the Middle East, today unveiled its whole ...
The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
According to the Uganda Cancer Institute (UCI), several factors contribute to the high burden of oncologic emergencies in Uganda, with late diagnosis being among the most significant.
Parade on MSN
TV Host John Tesh Is Still Fighting Rare Cancer 10 Years After Being Given 18 Months To Live
He was only given 18 months to live.
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...
Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results